BACKGROUND: Genetic variations of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) can affect diagnostic assays and therapeutic interventions. Recent changes in prevalence of subtypes/genotypes and drug/immune-escape variants were characterized by comparing recently infected vs more remotely infected blood donors. METHODS: Infected donors were identified among approximately 34 million US blood donations, 2006-2009; incident infections were defined as having no or low antiviral antibody titers. Viral genomes were partially sequenced. RESULTS: Of 321 HIV strains (50% incident), 2.5% were non-B HIV subtypes. Protease and reverse transcriptase (RT) inhibitor resistance mutations were found in 2% and 11% of infected donors, respectively. Subtypes in 278 HCV strains (31% incident) yielded 1a>1b>3a>2b>2a>4a>6d, 6e: higher frequencies of 3a in incident cases vs higher frequencies of 1b in prevalent cases were found (P = .04). Twenty subgenotypes among 193 HBV strains (26% incident) yielded higher frequencies of A2 in incident cases and higher frequencies of A1, B2, and B4 in prevalent cases (P = .007). No HBV drug resistance mutations were detected. Six percent of incident vs 26% of prevalent HBV contained antibody neutralization escape mutations (P = .01). CONCLUSIONS: Viral genetic variant distribution in blood donors was similar to that seen in high-risk US populations. Blood-borne viruses detected through large-scale routine screening of blood donors can complement molecular surveillance studies of highly exposed populations.
BACKGROUND: Genetic variations of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) can affect diagnostic assays and therapeutic interventions. Recent changes in prevalence of subtypes/genotypes and drug/immune-escape variants were characterized by comparing recently infected vs more remotely infected blood donors. METHODS: Infected donors were identified among approximately 34 million US blood donations, 2006-2009; incident infections were defined as having no or low antiviral antibody titers. Viral genomes were partially sequenced. RESULTS: Of 321 HIV strains (50% incident), 2.5% were non-B HIV subtypes. Protease and reverse transcriptase (RT) inhibitor resistance mutations were found in 2% and 11% of infected donors, respectively. Subtypes in 278 HCV strains (31% incident) yielded 1a>1b>3a>2b>2a>4a>6d, 6e: higher frequencies of 3a in incident cases vs higher frequencies of 1b in prevalent cases were found (P = .04). Twenty subgenotypes among 193 HBV strains (26% incident) yielded higher frequencies of A2 in incident cases and higher frequencies of A1, B2, and B4 in prevalent cases (P = .007). No HBV drug resistance mutations were detected. Six percent of incident vs 26% of prevalent HBV contained antibody neutralization escape mutations (P = .01). CONCLUSIONS: Viral genetic variant distribution in blood donors was similar to that seen in high-risk US populations. Blood-borne viruses detected through large-scale routine screening of blood donors can complement molecular surveillance studies of highly exposed populations.
Authors: Michael P Busch; Christopher D Pilcher; Timothy D Mastro; John Kaldor; Gaby Vercauteren; William Rodriguez; Christine Rousseau; Thomas M Rehle; Alex Welte; Megan D Averill; Jesus M Garcia Calleja Journal: AIDS Date: 2010-11-27 Impact factor: 4.177
Authors: Shimian Zou; Kerri A Dorsey; Edward P Notari; Gregory A Foster; David E Krysztof; Fatemeh Musavi; Roger Y Dodd; Susan L Stramer Journal: Transfusion Date: 2010-03-12 Impact factor: 3.157
Authors: Darrell E Singer; Christian T Bautista; Robert J O'Connell; Eric Sanders-Buell; Brian K Agan; Gustavo H Kijak; Shilpa Hakre; Jose L Sanchez; Warren B Sateren; Francine E McCutchan; Nelson L Michael; Paul T Scott Journal: AIDS Res Hum Retroviruses Date: 2010-08 Impact factor: 2.205
Authors: Ana Avellón; José M Echevarría; Bernard Weber; Michael Weik; Uwe Schobel; Wulf R Willems; Wolfram H Gerlich Journal: J Med Virol Date: 2011-01 Impact factor: 2.327
Authors: Susan L Stramer; Ulrike Wend; Daniel Candotti; Gregory A Foster; F Blaine Hollinger; Roger Y Dodd; Jean-Pierre Allain; Wolfram Gerlich Journal: N Engl J Med Date: 2011-01-20 Impact factor: 91.245
Authors: Shimian Zou; Susan L Stramer; Edward P Notari; Mary C Kuhns; David Krysztof; Fatemeh Musavi; Chyang T Fang; Roger Y Dodd Journal: Transfusion Date: 2009-08 Impact factor: 3.157
Authors: Mars Stone; John Bainbridge; Ana M Sanchez; Sheila M Keating; Andrea Pappas; Wes Rountree; Chris Todd; Sonia Bakkour; Mark Manak; Sheila A Peel; Robert W Coombs; Eric M Ramos; M Kathleen Shriver; Paul Contestable; Sangeetha Vijaysri Nair; David H Wilson; Martin Stengelin; Gary Murphy; Indira Hewlett; Thomas N Denny; Michael P Busch Journal: J Clin Microbiol Date: 2018-07-26 Impact factor: 5.948
Authors: Sumathi Ramachandran; Jamel A Groves; Guo-Liang Xia; Paula Saá; Edward P Notari; Jan Drobeniuc; Amanda Poe; Natasha Khudyakov; Sarah F Schillie; Trudy V Murphy; Saleem Kamili; Chong-Gee Teo; Roger Y Dodd; Yury E Khudyakov; Susan L Stramer Journal: Transfusion Date: 2018-11-30 Impact factor: 3.157
Authors: Sumathi Ramachandran; Michael A Purdy; Guo-liang Xia; David S Campo; Zoya E Dimitrova; Eyasu H Teshale; Chong Gee Teo; Yury E Khudyakov Journal: J Virol Date: 2014-09-03 Impact factor: 5.103
Authors: Shirin Ashraf; Katja Nitschke; Usama M Warshow; Collin R Brooks; Arthur Y Kim; Georg M Lauer; Theresa J Hydes; Matthew E Cramp; Graeme Alexander; Ann-Margaret Little; Robert Thimme; Christoph Neumann-Haefelin; Salim I Khakoo Journal: Hepatology Date: 2013-07-29 Impact factor: 17.425